RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2‑deficient human acute myeloid leukemia

Xu,Yichuan; Lin,Yansi; Luo,Yuxuan; Yang,Yanling; Long,Bing; Fang,Zhigang; Liu,Lingling; Zhang,Jingwen; Zhang,Xiangzhong

doi:10.3892/or.2020.7723

RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2‑deficient human acute myeloid leukemia

Authors:
- Yichuan Xu
- Yansi Lin
- Yuxuan Luo
- Yanling Yang
- Bing Long
- Zhigang Fang
- Lingling Liu
- Jingwen Zhang
- Xiangzhong Zhang
View Affiliations

Affiliations: Department of Hematology, The Third Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510630, P.R. China, Department of General Medicine, Sun Yat‑sen Memorial Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510120, P.R. China, Department of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong 510623, P.R. China
Published online on: August 10, 2020 https://doi.org/10.3892/or.2020.7723
Pages: 1455-1466
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

RAD52 (Radiation sensitive 52) is a key factor in DNA damage repair (DDR) bypass, which participates in single‑strand annealing (SSA) after DNA damage end excision, while breast cancer type 1 susceptibility protein (BRCA1)/breast cancer type 2 susceptibility protein (BRCA2) play critical roles in homologous recombination (HR) repair. The present study aimed to determine whether RAD52‑induced regulation of repair bypass occurs in acute myeloid leukemia (AML) cells and to explore the underlying mechanism. Herein, we applied an RAD52 aptamer to AML cells with downregulated BRCA1/2. RAD52 aptamer inhibited AML cell proliferation detected by cell counting, promoted cell apoptosis obtained by flow cytometry, and suppressed DNA damage repair behavior measured by comet assay and flow cytometry, after drug intervention during low expression of BRCA1/2. During this process, DDR‑related cell cycle checkpoint proteins were activated, and the cells were continuously arrested in the S/G2 phase, which affected the cell damage repair process. Concurrently, the expression levels of apoptosis‑related proteins were also altered. Furthermore, the expression of STAT3 and p‑STAT3 was downregulated by the RAD52 aptamer, suggesting that RAD52 affects the STAT3 signaling pathway. In summary, we present a possible role for RAD52 in DDR of BRCA1/2‑deficient AML cells that involves the STAT3 signaling pathway.

View Figures

View References

1	Moehrle BM and Geiger H: Aging of hematopoietic stem cells: DNA damage and mutations? Exp Hematol. 44:895–901. 2016. View Article : Google Scholar : PubMed/NCBI
2	Esposito MT and So CW: DNA damage accumulation and repair defects in acute myeloid leukemia: Implications for pathogenesis, disease progression, and chemotherapy resistance. Chromosoma. 123:545–561. 2014. View Article : Google Scholar : PubMed/NCBI
3	Biechonski S, Yassin M and Milyavsky M: DNA-damage response in hematopoietic stem cells: An evolutionary trade-off between blood regeneration and leukemia suppression. Carcinogenesis. 38:367–377. 2017. View Article : Google Scholar : PubMed/NCBI
4	Iyama T and Wilson DM III: DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst). 12:620–636. 2013. View Article : Google Scholar : PubMed/NCBI
5	Bhargava R, Onyango DO and Stark JM: Regulation of single-strand annealing and its role in genome maintenance. Trends Genet. 32:566–575. 2016. View Article : Google Scholar : PubMed/NCBI
6	Symington LS: Role of RAD52 epistasis group genes in homologous recombination and double-strand break repair. Microbiol Mol Biol Rev. 66:630–670, table of contents. 2002. View Article : Google Scholar : PubMed/NCBI
7	Rothenberg E, Grimme JM, Spies M and Ha T: Human Rad52-mediated homology search and annealing occurs by continuous interactions between overlapping nucleoprotein complexes. Proc Natl Acad Sci USA. 105:20274–20279. 2008. View Article : Google Scholar : PubMed/NCBI
8	Faraoni I, Compagnone M, Lavorgna S, Angelini DF, Cencioni MT, Piras E, Panetta P, Ottone T, Dolci S, Venditti A, et al: BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. Biochim Biophys Acta. 1852:462–472. 2015. View Article : Google Scholar : PubMed/NCBI
9	Scardocci A, Guidi F, D'Alo' F, Gumiero D, Fabiani E, Diruscio A, Martini M, Larocca LM, Zollino M, Hohaus S, et al: Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br J Cancer. 95:1108–1113. 2006. View Article : Google Scholar : PubMed/NCBI
10	Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, et al: Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood. 122:1293–1304. 2013. View Article : Google Scholar : PubMed/NCBI
11	Panier S and Boulton SJ: Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol. 15:7–18. 2014. View Article : Google Scholar : PubMed/NCBI
12	van Attikum H and Gasser SM: Crosstalk between histone modifications during the DNA damage response. Trends Cell Biol. 19:207–217. 2009. View Article : Google Scholar : PubMed/NCBI
13	Guan B and Zhang X: Aptamers as versatile ligands for biomedical and pharmaceutical applications. Int J Nanomedicine. 15:1059–1071. 2020. View Article : Google Scholar : PubMed/NCBI
14	Borghouts C, Kunz C and Groner B: Current strategies for the development of peptide-based anti-cancer therapeutics. J Pept Sci. 11:713–726. 2005. View Article : Google Scholar : PubMed/NCBI
15	Slupianek A, Dasgupta Y, Ren SY, Gurdek E, Donlin M, Nieborowska-Skorska M, Fleury F and Skorski T: Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood. 118:1062–1068. 2011. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Ciccia A and Elledge SJ: The DNA damage response: Making it safe to play with knives. Mol Cell. 40:179–204. 2010. View Article : Google Scholar : PubMed/NCBI
18	Stadler J and Richly H: Regulation of DNA repair mechanisms: How the chromatin environment regulates the DNA damage response. Int J Mol Sci. 18:17152017. View Article : Google Scholar
19	Gaul L, Mandl-Weber S, Baumann P, Emmerich B and Schmidmaier R: Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: The role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol. 134:245–253. 2008. View Article : Google Scholar : PubMed/NCBI
20	Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S and Zhang H: Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem. 278:21767–21773. 2003. View Article : Google Scholar : PubMed/NCBI
21	Rivlin N, Koifman G and Rotter V: p53 orchestrates between normal differentiation and cancer. Semin Cancer Biol. 32:10–17. 2015. View Article : Google Scholar : PubMed/NCBI
22	Vousden KH and Prives C: Blinded by the light: The growing complexity of p53. Cell. 137:413–431. 2009. View Article : Google Scholar : PubMed/NCBI
23	Bykov VJN, Eriksson SE, Bianchi J and Wiman KG: Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 18:89–102. 2018. View Article : Google Scholar : PubMed/NCBI
24	Bruserud Ø, Nepstad I, Hauge M, Hatfield KJ and Reikvam H: STAT3 as a possible therapeutic target in human malignancies: Lessons from acute myeloid leukemia. Expert Rev Hematol. 8:29–41. 2015. View Article : Google Scholar : PubMed/NCBI
25	Al Zaid Siddiquee K and Turkson J: STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 18:254–267. 2008. View Article : Google Scholar : PubMed/NCBI
26	Barry SP, Townsend PA, Knight RA, Scarabelli TM, Latchman DS and Stephanou A: STAT3 modulates the DNA damage response pathway. Int J Exp Pathol. 91:506–514. 2010. View Article : Google Scholar : PubMed/NCBI
27	Koganti S, Hui-Yuen J, McAllister S, Gardner B, Grasser F, Palendira U, Tangye SG, Freeman AF and Bhaduri-McIntosh S: STAT3 interrupts ATR-Chk1 signaling to allow oncovirus-mediated cell proliferation. Proc Natl Acad Sci USA. 111:4946–4951. 2014. View Article : Google Scholar : PubMed/NCBI
28	Deng WW, Hu Q, Liu ZR, Chen QH, Wang WX, Zhang HG, Zhang Q, Huang YL and Zhang XK: KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells. Mol Cell Biochem. 449:81–90. 2018. View Article : Google Scholar : PubMed/NCBI
29	De Groef S, Renmans D, Cai Y, Leuckx G, Roels S, Staels W, Gradwohl G, Baeyens L, Heremans Y, Martens GA, et al: STAT3 modulates β-cell cycling in injured mouse pancreas and protects against DNA damage. Cell Death Dis. 7:e22722016. View Article : Google Scholar : PubMed/NCBI
30	Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI